InnoCan PharmaINNPF -10.53%56 Pretax Margin % is -12.71% as of Mar. 2026. GuruFocus rates INNPF with a GF Score™ of 56/100 and a GF Value™ of $10.03 (Possible Value Trap). The stock has 2 warning signs investors should review. Among 1,950 Consumer Packaged Goods companies, InnoCan Pharma ranks worse than 79.54% on this metric.
The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
InnoCan Pharma Pretax Margin % Related Terms
InnoCan Pharma Pretax Margin % Historical Data
* Premium members only.
The historical data trend for InnoCan Pharma's Pretax Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Household & Personal Products subindustry, InnoCan Pharma's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
InnoCan Pharma Pretax Margin % vs Consumer Packaged Goods Industry
For the Consumer Packaged Goods industry and Consumer Defensive sector, InnoCan Pharma's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where InnoCan Pharma's Pretax Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
InnoCan Pharma (INNPF) has a Pretax Margin % of -12.71% as of Mar. 2026. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on InnoCan Pharma and its competitors. According to the industry distribution chart, InnoCan Pharma ranks #1551 out of 1950 companies in the Consumer Packaged Goods industry, placing it in the top 79.5%.
Is InnoCan Pharma's Pretax Margin % too high?
InnoCan Pharma's current Pretax Margin % is -12.71%. Based on the distribution chart, InnoCan Pharma ranks #1551 out of 1950 companies in the Consumer Packaged Goods industry, which is in the bottom quartile relative to peers. Overall, InnoCan Pharma has a GF Score™ of 56/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does InnoCan Pharma's Pretax Margin % compare to PG and CL?
According to the Consumer Packaged Goods industry distribution chart, InnoCan Pharma ranks #1551 out of 1950 companies for Pretax Margin %. This places InnoCan Pharma in the lower half of its industry. The industry median Pretax Margin % is 4.67. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Consumer Packaged Goods company?
The median Pretax Margin % among Consumer Packaged Goods companies is 4.67, based on 1,950 companies in the industry. Companies in the top quartile (top 25%) have a Pretax Margin % significantly above this median, while those in the bottom quartile fall well below. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on InnoCan Pharma and its competitors. For the Consumer Packaged Goods industry, the median Pretax Margin % is 4.67 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. InnoCan Pharma's current Pretax Margin % is -12.71%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is InnoCan Pharma stock overvalued right now?
Based on GuruFocus' analysis, InnoCan Pharma (INNPF) is currently considered Possible Value Trap. The stock's GF Value™ is $10.03, compared to a current price of $1.70 — trading 83.1% below its estimated fair value. The current Pretax Margin % is -12.71%. InnoCan Pharma's overall GF Score™ is 56/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For InnoCan Pharma (INNPF), the current Pretax Margin % is -12.71% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is InnoCan Pharma (INNPF) Overvalued in 2026?
Based on GuruFocus' analysis, InnoCan Pharma stock appears to be undervalued.
The current stock price of $1.70 is trading 83.1% below its estimated GF Value™ of $10.03.
GuruFocus considers InnoCan Pharma to be Possible Value Trap.
Key valuation signals for INNPF:
Pretax Margin %: -12.71%
GF Value™: $10.03 vs. price of $1.70 (83.1% below fair value)
No single metric tells the full story. See the INNPF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
InnoCan Pharma Corp develops consumer wellness and pharmaceutical products. It has developed a preclinical-stage Cannabidiol-loaded Liposome injection Platform (CBD-LPT) for non-opioid pain management, and is involved in developing and marketing various self-care and CBD beauty products. Additionally, the Group offers cosmetic products such as anti-aging beauty sleeping masks, anti-puffiness eye serum, anti-aging facial serum, hair cream, etc., which are sold mainly through online marketplaces. Its operating segments are: Online sales and Other operations. The majority of its revenue is generated from the Online sales segment, which engages in the development, manufacture, and marketing of cosmetic products. Geographically, the Group generates maximum revenue from the United States.
56GF Score
Get the complete analysis for INNPF
Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
INNPF has been successfully added to your 
